SGN-LIV1A is an auristatin-based ADC using the same drug-linker as brentuximab vedotin. It is targeted to LIV-1, a protein that is expressed in several types of solid tumors, including more than 90 percent of breast cancers. Preclinical data have demonstrated significant antitumor activity in multiple cancer models.


SGN-LIV1A is being evaluated in a phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave